Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues
May 30th, 2025
The present protocol describes the establishment and histological analysis of esophageal organoid models that represent different stages of tumor progression. This method enables researchers to study changes in cellular morphology, spatial organization, and molecular marker expression patterns during the transition from normal to cancerous tissues.
Our research focuses on tumor initiation and early tumorigenesis. We examine how normal cells transform into tumor cells, and how these cells modify their microenvironment to facilitate tumorigenesis. At present, there are many technologies used to promote research, including stem cell technologies, gene-editing technologies, advanced 3D culture system and biomaterials and single-cell and spatial omics technologies. The biggest challenge we face is keeping organoids free from bacteria and fungi. These contaminants sneak in during tissue handling and transport, often ruining our cultures.
[Instructor] To begin, thaw the basement membrane matrix and human esophageal organoid culture medium at four degrees Celsius. Transfer the tissue sample into five-milliliter centrifuge tubes, then wash the sample three times with room-temperature wash buffer. Using sterile scissors, mince the tissue into one-millimeter-cubed fragments in 1.5-milliliter centrifuge tubes. Now, suspend the tissue fragments in one milliliter of digestion buffer. Shake the mixture at 37 degrees Celsius at 50 to 100 revolutions per minute for 10 to 20 minutes to digest the tissue. Next, centrifuge the mixture at 400G for five minutes at four degrees Celsius. Then discard the supernatant. Resuspend the pellet in 500 microliters of 0.025% Trypsin-EDTA. Incubate the suspension at 37 degrees Celsius for 10 minutes. Then add one milliliter of DMEM supplemented with 10% fetal bovine serum to stop enzymatic activity. Next, pass the suspension through a 70-micrometer sterile filter and collect the filtrate into a 1.5-milliliter centrifuge tube. Centrifuge the filtrate for five minutes at 400G at four degrees Celsius. Resuspend the cells in 100 microliters of H-EOCM after discarding the supernatant. After resuspending cells, determine the cell density by using a cell counter. Then transfer 5,000 to 15,000 cells per milliliter into a fresh 1.5-milliliter tube. For organoid seeding, gently resuspend cells in 50 to 100 microliters of basement membrane matrix. Pipette 50 microliters of the matrix cell mixture to the center of each well of a 24-well plate. Incubate at 37 degrees Celsius for 30 minutes to polymerize the basement membrane matrix. Now pipette 500 microliters of prewarm H-EOCM to each well to cover the matrix. Then incubate the plate in a humidified incubator with 5% carbon dioxide at 37 degrees Celsius. To replace the medium, aspirate the spent medium. Replenish each well with 500 microliters of fresh H-EOCM prewarmed to 37 degrees Celsius. To perform multiplex immunofluorescence staining on reparaffinized and rehydrated organoids. Add sheep serum-blocking solution to cover the organoids on a slide placed in a humidity chamber and incubate the slide at room temperature for 30 minutes. Wash the slide with PBS-containing Tween for two minutes. Next, drop diluted primary antibody to cover the organoid area. Incubate in a humidity chamber according to antibody requirements. After incubation, wash the slides in PBS-T two times for two minutes at 80 PMM in a thermostable chamber. Now drop secondary antibody solution onto the organoid area and incubate in a humidity chamber at room temperature for 20 minutes. After incubation, wash the slides in PBS-T two times for two minutes at 80 RPM in a thermostable chamber. Pipette fluorescent dye solution over the washed slide to cover the organoid area and incubate again. After incubation, wash the slides in PBS-T two times. For multistaining, repeat antigen retrieval and antibody blocking. Then drop dappy solution to cover the organoid area. Immerse the slides in sterilized water for two minutes to wash away the excess stain. Add antifade mounting medium and apply cover slip before acquiring digital images. Organoid structures became increasingly disorganized from normal to carcinoma stages, as visualized by KRT6A staining. Expression of PDL1 progressively increased from normal esophageal mucosa to esophageal squamous cell carcinoma.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol outlines the establishment and histological analysis of esophageal organoid models that reflect various stages of tumor progression. It allows researchers to investigate cellular morphology, spatial organization, and molecular marker expression changes from normal to cancerous tissues.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Cell Biology
Background
- Research focuses on tumor initiation and early tumorigenesis.
- Normal cells can transform into tumor cells, altering their microenvironment.
- Technologies used include stem cell, gene-editing, and 3D culture systems.
- Contamination from bacteria and fungi poses challenges during tissue handling.
Purpose of Study
- To establish organoid models for studying tumor progression.
- To analyze changes in cellular and molecular characteristics during tumor development.
- To provide insights into the transition from normal to cancerous tissues.
Methods Used
- Thawing basement membrane matrix and culture medium.
- Washing and digesting tissue samples to create organoid cultures.
- Multiplex immunofluorescence staining for histological analysis.
- Monitoring changes in organoid structure and molecular expression.
Main Results
- Organoid structures showed increasing disorganization from normal to carcinoma stages.
- KRT6A staining visualized morphological changes.
- PDL1 expression increased progressively from normal to cancerous tissues.
- Successful establishment of organoid cultures free from contamination.
Conclusions
- The protocol enables detailed study of esophageal tumor progression.
- Histological analysis provides insights into cellular changes during tumorigenesis.
- Organoid models are valuable for understanding cancer biology.
Frequently Asked Questions
Executive Industry Relevance
Human esophageal organoid models enable biopharma teams to interrogate the cellular and molecular transitions from normal to cancerous states, supporting predictive confidence in early oncology discovery. Quantitative histological analysis of spatial architecture and biomarker expression informs target validation and mechanistic de-risking at critical pipeline inflection points. These models facilitate translational continuity by bridging discovery biology with preclinical evaluation of therapeutic hypotheses.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic interrogation of tumorigenic pathways and cellular transformation events.
- Supports functional validation of candidate targets through spatial and molecular biomarker analysis.
- Provides mechanistic de-risking by modeling disease progression in a controlled 3D system.
- Facilitates portfolio triage by revealing stage-specific molecular alterations.
Screening & Assay Development
- Prepares validated organoid systems for downstream compound screening and phenotypic assays.
- Standardizes histological and immunofluorescence readouts for reproducible quantitative outputs.
- Enables scalable, multiplexed analysis of biomarker expression across tumor stages.
- Supports reliable evaluation of therapeutic interventions in disease-relevant contexts.
Translational & Preclinical Research
- Aligns organoid-derived biomarker changes with translational endpoints for preclinical studies.
- Maintains continuity from discovery through preclinical validation by modeling tumor progression.
- Informs risk-adjusted advancement decisions based on quantitative molecular and morphological data.
- Provides predictive de-risking for candidate therapies targeting esophageal cancer pathways.
Pipeline & Workflow Integration
This organoid protocol integrates into the oncology discovery continuum from early target validation through preclinical research, enabling iterative hypothesis testing and biomarker-driven decision-making.
- Discovery Biology: Supports hypothesis testing on tumor initiation and progression using spatial and molecular analyses.
- Screening: Delivers reproducible, quantitative histological and immunofluorescence outputs for assay development.
- Analytics: Provides digital imaging and multiplexed biomarker measurements for comparative condition analysis.
- Translational Research: Bridges discovery findings with preclinical biomarker alignment and disease modeling.
- Enterprise Reuse: Establishes a reusable organoid platform adaptable to various tumor stages and intervention studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes organoid culture, staining, and imaging workflows for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management in oncology R&D.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of therapeutic candidates targeting esophageal cancer.
Implementation Considerations
- Requires expertise in 3D cell culture, histology, and immunofluorescence techniques.
- Demands access to sterile tissue handling, advanced imaging, and analytical infrastructure.
- Necessitates rigorous cross-team standardization to prevent contamination and ensure data quality.
- Adaptable across different tumor stages and molecular targets within esophageal cancer research.
- Contamination risk during tissue handling is a practical limitation requiring strict protocol adherence.
